
    
      Treatment must be continued for up to 4 three-weekly cycles or 6 bi-weekly cycles, or for up
      to a maximum of 12 weeks. Subjects with CR/PR/SD after oxaliplatinum compound and
      fluoropyrimidine-based regimens, or without evidence of progressive disease in case of
      non-measurable disease, will be randomized in 1:1 ratio between the two treatment arms.

      Prior to randomization, subjects will be stratified based on Center; Prior gastrectomy: No
      vs. Yes; Peritoneal carcinomatosis: Yes vs. No; Site of origin: GEJ vs. gastric.
    
  